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Abstract
Purpose: The purpose of this study was to conduct an initial needs assessment on the TAVR
program at Norton Healthcare (NHC). Baseline data were collected on patient quality of life as
evidenced by Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, frailty scores, Katz
index, Lawton scale, Society of Thoracic Surgeons (STS) mortality score, and comorbidities. A
secondary purpose was to identify trends in patient outcomes such as increased morbidity,
mortality, readmission rates, complications, discharge disposition, and increased length of stay.
Setting and Population: The population for this study was all patients at Norton Audubon
Hospital (NAH) who underwent TAVR between October 1, 2014 and December 31, 2015. A
total of 51 patients were included in the chart review.
Procedures: This needs assessment utilized a retrospective electronic medical record review. The
records were assigned a study number that was used on all electronic data collection forms. Data
were collected using an investigator developed data collection instrument. The data were then
directly entered into Data Analysis Statistical Package for the Social Sciences (SPSS) software
for analysis.
Results and Conclusions: A review of the patients’ health history and co-morbid burden was
conducted. Forty-three patients (84.3%) had hypertension, 33 (64.7%) had coronary artery
disease or a myocardial infarction, 37 (72.5%) had hyperlipidemia, nine (17.6%) had a
permanent pacemaker and/or AICD, 14 (27.5%) had previous coronary artery bypass grafting
(CABG), 24 (47.1%) had an arrhythmia such as atrial fibrillation, 11 (21.6%) had a previous
stroke, 26 (51%) had some form of pulmonary disease, 16 (31.4%) had some form of renal
disease, 12 (23.5%) had history of cancer, and 13 (25.5%) were diabetic. Pre-procedure quality
of life metrics were examined using KCCQ scores, Katz index, Lawton scale, STS score, and
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frailty score were included. The mean pre-procedure KCCQ score (n=50) was 29.16
(SD=11.919), Katz index (n=35) was 5.26 (SD= 1.094), Lawton scale (n=35) was 4.71 (SD=
2.573), STS score (n=51) was 12.28535 (SD= 5.638508), and frailty score (n=19) was 5.11 (SD=
1.100). Post-procedure metrics included 30-day KCCQ score, length of stay, discharge
disposition, and 30-day readmission. The mean 30-day KCCQ score (n= 27) was 47.96
(SD=10.886). The median length of stay was five days. Thirty-three (64.7%) were discharged
home, 13 (25.5%) went to a sub-acute rehabilitation facility, one (2%) went to the Veterans
Affairs Medical Center (VAMC), three (5.9%) died, and one (2%) went to a long-term acute care
(LTAC) facility. Seven patients (13.7%) were readmitted to a Norton facility within thirty days
of being discharged from the hospital.
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Background
As patients age, calcium can build up on the leaflets of their aortic valve. The valve will
become stiff, making it unable to open and close properly leading to a condition called aortic
stenosis (AS). With the disease sequlea of AS, symptoms of angina, fatigue, shortness of breath,
and syncope will occur. According to the website for the Edwards Lifesciences New Heart
Valve, more than one in eight patients over the age of 75 will have moderate to severe aortic
stenosis. In fact, once patients begin exhibiting symptoms of severe AS, they only have a 50
percent chance of living two more years without a valve replacement. (Edwards Lifesciences
New Heart Valve website, 2015). Transcatheter aortic valve replacement (TAVR) was developed
in 2002 as an alternative to surgical aortic valve replacement (SAVR) for patients that had been
deemed non-surgical candidates or high risk for surgical intervention. Thirty percent of patients
with severe AS will not be candidates for SAVR due to advanced age, poor left ventricular
dysfunction, or multiple comorbidities (Leon et al., 2010). Patients are quantified as high
operative risk utilizing the STS mortality score. The STS score takes many factors into account
including age, renal function, left ventricular dysfunction, underlying coronary disease, comorbid
lung disease as well as re-operative heart surgery status and other comorbid conditions.
However, it does not quantify a patient’s frailty and functional status. A percentage of the
patient’s overall mortality for an open SAVR is given with the STS mortality score. With the
indications for the PARTNER trial and original FDA indications, a patient with an overall STS
mortality score greater than 8% is considered high operative risk. The STS scale has been
utilized in the TAVR trials all around the country and found to be more reliable than other
mortality scales. It is measured from 0-100%.
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There have been several studies showing the benefit of TAVR in the high operative risk
aortic stenosis patient. The Placement of Aortic Transcatheter Valves (PARTNER) trial was a
multicenter, randomized clinical trial sponsored by Edwards Lifesciences. The PARTNER trial
compared patients who underwent TAVR to those who received standard therapy. Between May
11, 2007, and March 16, 2009, a total of 358 patients with severe aortic stenosis who were not
suitable candidates for surgery were enrolled at 21 sites (17 in the United States) and were
randomly assigned to TAVR using the Edwards Lifesciences heart valve (179 patients) or
standard therapy (179 patients). Standard therapy consists of medication and may include
balloon aortic valvuloplasty. The study showed that patients who underwent TAVR had lower
endpoint mortality rate, fewer repeat hospitalizations, and improved cardiac symptoms than the
standard therapy group (Leon et al., 2010).
The PARTNER II trial was a follow up to the PARTNER trial and included patients who
were of intermediate STS risk score (Leon et al., 2016). It also showed results comparable to
SAVR. In the PARTNER II trial the indications were expanded to the intermediate risk patients
with AS. Another study, conducted using the Medtronic Core Valve, a self-expanding valve,
showed similar outcomes. Patients who were high risk or not candidates for SAVR, showed
improved health status after undergoing TAVR (Arnold et al., 2015).
A follow up report utilizing the PARTNER study was released in 2015 with the five-year
trial results. It showed TAVR outcomes to be superior to standard therapy with a decrease in the
stroke risk. The researchers found that without treatment 94% of patients in the standard therapy
group died within five years. In the treatment group of randomized TAVR patients there was
21.8% absolute reduction in mortality at five years (Kapadia et al., 2015).
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The functional scales utilized to evaluate patients for TAVR have been extensively
reviewed in the literature for their validity and reliability. The Katz Index of Independence in
Activities of Daily Living ranges (Shelkey, 2012) 0 to 6 (lower scores indicating poorer
functionality) and measures activities of daily living (ADLs). These are routine activities that
people perform everyday without needing assistance. The six basic ADLs include eating,
bathing, dressing, toileting, transferring (walking) and continence. Instrumental activities of daily
living (IADLs), are measured using the Lawton Instrumental Activities of Daily Living Scale
(Graf, 2008), which is scored 8 to 0 (again lower scores indicates lower functionality). These
activities are not necessary for fundamental functioning, but they are required to function
independently in a community. The IADLs include housework, preparing meals, taking
medications as prescribed and managing money. The Clinical Frailty Score (Dalhousie
University, 2015) is a scale in which the provider determines the patients overall fitness and
ability to perform ADLs and IADLs. It is measured 1 to 9 (lower scores indicate higher
functionality). It is a subjective scale but allows the provider to utilize clinical judgment in
functionality. The Katz and Lawton scales are both determined by the patient.
The area served by NHC has a very high volume of heart disease given the geographical
region. NHC services Jefferson County Kentucky, the neighboring counties of Oldham, Shelby,
Spencer, and Bullitt, as well as southern Indiana. This area lies along the Ohio River and
includes both urban and rural communities. In a report entitled, “Heart Disease Hospitalization
Rates by State, Medicare Beneficiaries Ages 65 and Older, 2000–2006” Kentucky is at 92.8 per
1,000 admissions and the US is 75.2 per 1,000 admissions. Only Louisiana and West Virginia
were calculated at a higher number of admissions than Kentucky (Casper et al., 2009). This helps
illustrate the importance of a successful TAVR program at NHC.
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Purpose
The purpose of this project was to conduct a needs assessment for the TAVR program at
NHC. A needs assessment is a systematic approach that progresses through a defined series of
phases. It focuses on the outcomes to be attained, rather than the process. The results of a needs
assessment will aid in further setting priorities and determines criteria for solutions in the area of
interest to make sound decisions. A needs assessment sets criteria for determining how best to
allocate available money, people, and other resources.
Baseline data were collected on patient quality of life as evidenced by Kansas City
Cardiomyopathy Questionnaire (KCCQ) scores, Katz Index of Independence in Activities of
Daily Living, Lawton Instrumental Activities of Daily Living Scale (see appendices A, B, and
C), frailty score, and other quality metrics including 30-day hospital readmission rate, STS
overall mortality score, length of stay, discharge disposition, and common complications
including stroke, acute renal failure, convert to sternotomy, the need for permanent pacemaker,
and vascular complications. Also collected were pre-procedure comorbid conditions. These comorbidities were chosen for their strong connection to heart disease and/or poor functional
status. The second aim of this project was to identify trends in patient outcomes such as
increased morbidity and mortality, readmission rates, discharge disposition, and increased length
of stay that decreased quality of life.

Methods
Approval was obtained from the Norton Healthcare Office of Research Administration
(NHORA) and the University of Kentucky Institutional Review Boards for expedited review for
research involving human subjects prior to data collection. This project was a needs assessment
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using a retrospective electronic medical record (EMR) review of all patients between the ages of
60 and 100 who underwent TAVR at NHC from October 1, 2014 to December 31, 2015. Data
were collected from the EMR of these patients who were also the first 51 patients to undergo
TAVR at NHC. All patients who underwent TAVR at NAH after December 31, 2015 were
excluded. Note that all TAVR procedures at NHC are performed at Norton Audubon Hospital
(NAH). A data collection instrument was developed and is included in Appendix D. The data
were then analyzed for trends and compared to national outcomes. Based on the data collected,
recommendations have been made for the TAVR program at NHC as well as future research.
Research questions addressed were:
•

What are the current gaps in care of the TAVR program at Norton Healthcare?

•

What is the comparison of Norton Healthcare to other facilities in the nation in
regards to TAVR patient outcomes?

•

Where can Norton Healthcare take steps to improve patient outcomes in the TAVR
population?
Procedures

This study design was a retrospective descriptive electronic medical record review of all
patients who underwent TAVR at Norton Healthcare between October 1, 2014 and December
31, 2015. The records were assigned a study number that was used on all electronic data
collection instruments. Data were collected on the data collection instrument depicted in
Appendix D, which was kept secure on Norton’s H drive, along with the master list during the
data collection process. The H drive is both password and firewall protected. The data was then
entered into statistical analysis software. Data Analysis Statistical Package for the Social
Sciences (SPSS) software was used in the analysis of data.
7

TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR)
No identifiable data were reported in this study. Upon completion of the study, the
primary investigator (PI) will have deleted the password-protected documents that contain
patient personal medical record numbers using data overwriting software to ensure that the data
will not be reconstituted. The PI maintained study data with study numbers so as to perform
further analysis and validate the accuracy of data. Data collected will be maintained for six years
after study completion. At that time, electronic data files will be deleted according to Norton
Healthcare’s policy for deleting electronic files.

Results
Sample Characteristics
Included in the study were 19 (37.3%) males and 32 (62.7%) females with an average age
of 81.02 (SD 7.22) years. Fifty (87.7%) were Caucasian and one (1.8%) was African American
(see Table 1). All patients had a classification of NYHA stage III or IV heart failure prior to their
procedure and were in need of an aortic valve replacement.
As mentioned previously, at the time of the chart review, FDA indications for TAVR
only included those deemed inoperative or high operative risk. TAVR was not approved for
intermediate risk patients until after the time frame of this study. All patients reviewed in this
needs assessment were deemed non-operable or high-risk and their STS mortality risk scores
were greater than 8%.

Study Results
A review of the patients’ health history was conducted, which examined 11 different
preselected comorbidities (see Figure 1). Forty-three (84.3%) had hypertension, 33 (64.7%) had
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coronary artery disease or a myocardial infarction, 37 (72.5%) had hyperlipidemia, nine (17.6%)
had a permanent pacemaker and/or AICD, 14 (27.5%) had had a CABG previously, 24 (47.1%)
had an arrhythmia such as atrial fibrillation, 11 (21.6%) had had a previous stroke, 26 (51%) had
some form of pulmonary disease, 16 (31.4%) had some form of renal disease, 12 (23.5%) had
had cancer, and 13 (25.5%) were diabetic.
Next, pre-procedure quality of life metrics were examined (see Table 2) which included
KCCQ scores, Katz index, Lawton scale, STS scores, and frailty score. Unfortunately not all
participants had their scores recorded in the electronic medical record. Some were well
documented, such as pre-procedure KCCQ score (N=50) and STS score (n=51), but others had
less than half recorded, such as the frailty score (n=19).
The mean pre-procedure KCCQ score (n=50) was 29.16 (SD=11.919), Katz index (n=35)
was 5.26 (SD= 1.094), Lawton scale (n=35) was 4.71 (SD= 2.573), STS score (n=51) was
12.28535 (SD= 5.638508), and frailty score (n=19) was 5.11 (SD= 1.100).
Post-procedure metrics included 30-day KCCQ score, length of stay, discharge
disposition (see Figure 2), and 30-day readmission. The mean 30-day KCCQ score (n= 27) was
47.96 (SD=10.886). The median length of stay was five days. Thirty-three (64.7%) were
discharged home, 13 (25.5%) went to a sub-acute rehabilitation facility, one (2%) went to the
Veterans Affairs Medical Center (VAMC), three (5.9%) died, and one (2%) went to a long-term
acute care (LTAC) facility. Seven patients (13.7%) were readmitted to a Norton facility within
30 days.
Discussion
In October 2014, Norton Healthcare (NHC) performed its first TAVR procedure at
Norton Audubon Hospital. Since then NHC has performed over 100 procedures and the program
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is anticipated to perform higher volumes with the new FDA indications for intermediate risk
patients.
As shown in the results of this study, the program has struggled with getting patients to
comply with post-operative follow-up and routine follow-up care, attending follow-up
appointments, and required follow-up testing and surveys. Many of the quality of life metrics
were under reported showing a lack of reporting and follow-up either on the part of the
healthcare provider or the patient. Thirty patients (52.6%) did not have a 30-day KCCQ
recorded, 38 (66.7%) did not have a frailty score, and 22 (38.6%) did not have a Katz index or
Lawton scale reported. Metrics that are consistently documented are more reliable than those that
are not. Generalizations to the entire TAVR population can be deduced using the data of more
consistently collected data. Metrics with less consistent documentation are more likely to be
biased and lead to incorrect assumptions.
The only directly comparable metric was the pre-procedure KCCQ score and the 30-day
KCCQ score. A higher KCCQ score implies less severe heart failure symptoms and a better
quality of life. It measures how often activities are limited by their heart failure, leg swelling,
fatigue, shortness of breath, and how often heart failure has limited the enjoyment of their life.
The mean pre-procedure KCCQ score was 29.16 (SD=11.919) and the mean 30-day KCCQ
score was 47.96 (SD=10.886). Although this shows an improvement in the quality of life for
patients after undergoing the TAVR procedure, the low number of 30-day KCCQ scores (n=27)
makes generalization and reliability of this finding poor. Had more scores been reported, this
finding would have ben stronger.
National statistics were similar to what was found in this study. A report from the
STS/ACC TVT registry showed 50.5% of patients with TAVR procedures from 2012 to 2014
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were male, with a mean age of 82 years. Less than 5% of all TAVR patients nationally were
African American. Common comorbidities listed in the national database were prior
revascularization (either percutaneous coronary intervention or coronary artery bypass graft),
prior stroke, diabetes, peripheral arterial disease, moderate or severe chronic lung disease and
prior myocardial infarction. Approximately 83% of patients were in New York Heart
Association functional class III/IV. Approximately 82% had evidence of frailty, the mean KCCQ
score (reported in 76% of patients) was 41, indicating poor health status, including reduced
function and quality of life. Finally, a history of or current atrial fibrillation was identified in
approximately 41% of patients. This is representative of all TAVR patients across the United
States.
When compared to average STS scores of TAVR patients from PARTNER I, PARTNER
II, and Medtronic trials, the patients who underwent TAVR at NHC had significantly higher
scores. This may be related to the population in the region serviced by NHC having overall
poorer health. Patient selection could have also been of influence here with the higher STS
scores.

Implication for Practice
There are many factors that can reduce quality of life. One particular study identified that
these factors include but are not limited to physical limitation, debilitating symptoms, difficulties
coping with treatment, lack of knowledge, distress emotions, multiple comorbidities, and other
personal struggles (Riegel & Carlson, 2002). This study recommended a stepped approach to
patient education and counseling, an approach that may be beneficial in the TAVR population at
NHC. Utilizing this practice model at NHC could potentially aid patients in adhering to their
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treatment plan with regard to following up with their providers. There have been several research
studies on ways to improve patient adherence to treatment regimens, but none have been
conclusive. One article suggested that multiple approaches be utilized, such as educating
patients, providing written action plans, shortening the time interval between office visits,
simplifying treatment regimens, and providing patients with reminder strategies (Aslam, 2015).
A standardized plan for providers to utilize for data collection and data entry is also
needed in order to make research more accurate. Placing the frailty instrument into the EMR is
one way we can improve adherence to collection on behalf of the providers. With accurate data,
providers will be able to clearly see what is working well and where improvements in the
program can be made. Many facilities have created an APRN or RN role for a nurse who is
responsible for ensuring all pre- and post- procedure testing and appointments are completed and
that all data are properly collected and entered into the EMR. For NHC to create this role,
leadership will need to approve it and then they will need to hire and educate an individual for
the position.

Implications for Future Inquiry
The data from this study shows the importance of program monitoring to ensure
continued positive patient outcomes. Future studies should include follow-up of this needs
assessment with patients who have undergone TAVR at NAH since January 1, 2016. The volume
of patients who undergo TAVR at NAH has increased so there will be the need for a larger
number of records which will need to be reviewed and evaluated. As the numbers increase, this
will make data more reliable and generalizable to the TAVR population. Also, the electronic
medical records of patients who have undergone TAVR at NHC more recently will be more
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complete as the protocol for entering and collecting data has improved. A TAVR nurse was hired
to aid with patient education, appointment scheduling, and data entry. A study of more recent
patients can be compared to this study to show the evolution of the TAVR program at NHC and
any changes to the program, such as the TAVR nurse position, can be evaluated based on patient
outcomes.

Limitations
The small sample size (n=51) was a significant limitation in this study. The small sample
has made the data less reliable. Also, the newness of the TAVR program is a limitation. The
experience of the providers and the process for choosing participants has evolved since the
beginning of the program; therefore more recent patients have had more success. Finally, the
omission of data on the part of the provider and the lack of follow-up on the part of the patient at
one month, three months, and one year have limited the accuracy and of the study findings. Data
omission likely occurred because of lack of protocols for data collection. Multiple providers
were collecting data and no one person had ownership of data entry, which contributed as well to
possible omissions of data. Following the completion of this study, a TAVR nurse position was
established and it is one of his/her responsibilities to ensure that all required testing be completed
and data be entered in a timely and uniform fashion.

Conclusion
Due to the newness of the TAVR program at NHC, continued and frequent analysis of
the program and patient outcomes, and comparison to national benchmarks are necessary to
maintain a safe and effective program. One area for improvement is improved adherence to the
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documentation protocol by providers. Without collecting the data and accurate reporting, any
areas for improvement may not be identified. For the TAVR program to maintain positive
outcomes for patients and minimize complications, it is important that the ability to monitor
outcomes be achieved. Another area of improvement is completion of pre-procedure patient
education so that patients are fully aware of the post-procedure requirements. This will make the
patients more likely to keep their follow-up appointments at one month, three months, and one
year. Implementing follow-up appointments that are made prior to discharge and setting up
reminder calls and text messages prior to each appointment has proven beneficial in other
programs. Having a standard process as well as a designated person responsible for collecting
and reporting data on the part of the providers will make omitted data from the EMR less likely.
NHC has taken steps to implement a process used by other centers and recommended in the
PARTNER study by hiring a TAVR nurse coordinator. This nurse coordinator is responsible for
all data collection and documentation as well as contacting patients for appointments. This is a
new position and was not in place at the time of the study, therefore, this limitation may have
already been resolved.
As the TAVR program at NHC continues to grow and evolve, and use of technology
improves, the ability to help this particular patient population will also improve. Norton
Healthcare’s continued dedication to its patients and healthcare providers is evident in its
continued work to attain the highest standard of care for the people in this community and bring
cutting edge treatments and therapies to this area.
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Table 1.
Demographic Characteristics of Study Sample (N = 51)
Age, Mean (SD)
Sex, n(%)
Male
Female
Race, n(%)
Caucasian
Other

81.02 (7.22)
19 (37.3)
32 (62.7)
50 (87.7)
1 (1.8)
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Table 2.
Quality of Life Metrics
Mean (SD)
29.16 (11.919)

Pre-procedure KCCQ score (n=50)
Katz Index (n=35)

5.26 (1.094)

Lawton Score (n=35)

4.71 (2.573)

STS score (n=51)

12.28535 (5.638508)

Frailty score (n=19)

5.11 (1.100)

30-day KCCQ score (n=27)

47.96 (10.886)
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Figure 1. Comorbidities (N= 51)
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Figure 2. Discharge Disposition
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Appendix A
The Lawton Instrumental Activities of Daily Living Scale
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Appendix B
Katz Index of Independence in Activities of Daily Living
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Appendix C
Kansas City Cardiomyopathy Questionnaire (KCCQ-12)
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Appendix D
Data Collection Tool

Patient 1

Patient 2

Age
Sex
Ethnicity
Comorbidities:
ARF, HTN, prior
CABG, stroke,
DM, etc.
Pre-procedure
KCCQ score
30 day KCCQ
score
Frailty score
Length of stay
Discharge
Disposition
Complications:
Stroke, ARF,
PPM, vascular
complications,
convert to
sternotomy,
death
Katz Index
Lawton scale
STS mortality
score
30-day
readmission
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Appendix E
Letter of Approval: NHORA

Office of Research Administration (NHORA)
224 E. Broadway Louisville, KY 40202 (502) 629-3501 Phone (502) 629-3480 Fax
nhora@nortonhealthcare.org www.nortonhealthcare.org
May 25, 2016
Anna Chumbley, RB, DNPs 1 Audubon Plaza Louisville, KY 40217
NHORA# 16-N0091/ IRB# 16-0352-P2H / Transcatheter Aortic Valve Replacement (TAVR): A Needs
Assessment for Norton Healthcare Dear Ms. Chumbley:
The Norton Healthcare Office of Research Administration (NHORA) is pleased to notify you that your
application to conduct the above-mentioned research study in the following Norton Healthcare (NHC)
facility has been approved.
• Norton Audubon HospitalPlease note: NHORA approval reflects permission to conduct the study
within a Norton Healthcare facility from a regulatory and contractual perspective, and is
independent of approval by the sponsor for initiation of the study. The sponsor or site may have
additional requirements to address before the study can begin. The following items must be submitted to
the NHORA if your study continues to be conducted in a NHC facility and are applicable to your study:
• Annual Progress Report/Continuation Review form 
• Annual Approval letters and current Informed Consent Forms approved by the IRB, if
applicable 
• Amendments and Amendment Approval letters 
• Revised HIPAA documents such as revised Partial Waivers/Complete Waivers of authorization
for each change in personnel 
• Changes in the Conflict of Interest status 
• Status change of study, i.e. closed to enrollment, study termination etc. To comply with HIPAA
regulations: 
• A copy of the Partial Waiver of Authorization must be filed with the medical record of every
patient screened for the study, if applicable. 
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• For retrospective chart reviews, a copy of the Complete Waiver of Authorization must be filed
with the medical record of every patient whose chart is reviewed for the study. For studies
utilizing an Informed Consent Form, a signed copy of the Informed Consent Form and
Research Authorization must be filed with the medical record of each subject enrolled in
your study in a NHC facility. If applicable, the Research Patient ID form must be submitted
to NHORA Billing daily with reportable activity. Please email the form to
NHORABilling@nortonhealthcare.org. Please contact Regina Schaefer at 502-629-3580 for
specific instructions regarding the notification of your subject enrollment at NHC. If the
study will include the use of sponsor provided and/or personal equipment of any type (for
example: tablets, ECG machines, ePROs, personal laptops etc.), that equipment must be
checked, tracked and/or inspected by Norton Healthcare’s Clinical Engineering department
prior to its use or placement in a patient care setting. Request an initial incoming inspection
of the equipment as follows: 
• Norton employed researchers – contact Clinical Engineering on NSITE at
http://nsite/departments/clinicalengineering/SitePages/Home.aspx
• Non-Norton employed researchers – contact Clinical Engineering by calling 502-629-3590 In the
event your study will utilize personal and/or sponsor provided equipment, please ensure that you
comply with the procedure outlined above. We look forward to the successful completion of your
study. If you have any further questions or need assistance, please contact the NHORA at (502)
629-3501. Please let us know how we are doing. Follow the link
https://www.surveymonkey.com/s/NHORAsatisfaction to complete the NHORA Satisfaction
Survey in less than two minutes. Your feedback helps NHORA improve the services we provide
and meet the needs of the research community. Sincerely, Rhonda Hoffman System Director
Research Norton Hospital ︎ Kosair Children’s Hospital
Norton Audubon

Hospital Norton Suburban Hospital
Brownsboro Hospital

Norton Immediate Care Centers Norton
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Appendix F
Letter of Approval: University of Kentucky IRB

Expedited Initial Review

Approval Ends May 15, 2017
TO:
FROM:
IRB Number 16-0352-P2H
Anna Chumbley, RB, DNPs College Nursing c/o Tricia MacCallum 202 CON Bldg. 0232
PI phone #: (502)759-0587
Chairperson/Vice Chairperson Medical Institutional Review Board (IRB)
Approval of Protocol Number 16-0352-P2H May 19, 2016
SUBJECT: DATE: On May 16, 2016, the Medical Institutional Review Board approved your
protocol entitled:
Norton Transcatheter Aortic Valve Replacement (TAVR): A Needs Assessment for Norton
Healthcare
Approval is effective from May 16, 2016 until May 15, 2017 and extends to any consent/assent
form, cover letter, and/or phone script. If applicable, attached is the IRB approved consent/assent
document(s) to be used when enrolling subjects. [Note, subjects can only be enrolled using
consent/assent forms which have a valid "IRB Approval" stamp unless special waiver has
been obtained from the IRB.] Prior to the end of this period, you will be sent a Continuation
Review Report Form which must be completed and returned to the Office of Research Integrity
so that the protocol can be reviewed and approved for the next period.
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In implementing the research activities, you are responsible for complying with IRB decisions,
conditions and requirements. The research procedures should be implemented as approved in the
IRB protocol. It is the principal investigators responsibility to ensure any changes planned for the
research are submitted for review and approval by the IRB prior to implementation. Protocol
changes made without prior IRB approval to eliminate apparent hazards to the subject(s) should
be reported in writing immediately to the IRB. Furthermore, discontinuing a study or completion
of a study is considered a change in the protocol’s status and therefore the IRB should be
promptly notified in writing.
For information describing investigator responsibilities after obtaining IRB approval, download
and read the document "PI Guidance to Responsibilities, Qualifications, Records and
Documentation of Human Subjects Research" from the Office of Research Integrity's IRB
Survival Handbook web page [http://www.research.uky.edu/ori/IRB-SurvivalHandbook.html#PIresponsibilities]. Additional information regarding IRB review, federal
regulations, and institutional policies may be found through ORI's web site
[http://www.research.uky.edu/ori]. If you have questions, need additional information, or would
like a paper copy of the above mentioned document, contact the Office of Research Integrity at
(859) 257-9428.

Robyn Cheung, PhD, RN, MSN, ARNP
Chairperson/Vice Chairperson

An	
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  Opportunity	
  University	
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160352P2H Norton Transcatheter Aortic Valve Replacement (TAVR): A
Needs Assessment for Norton Healthcare
Verified "Consent Authorized" N PI Chumbley Anna

akch2261@uky.edu
KP Burckardt Elizabeth Elizabeth.Burckardt@uky.edu
CITI through UofL
KP Melander Sheila sheila.melander@uky.edu
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Authorized
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